Biotech News

Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates

Assembly Biosciences (ASMB)Assembly BiosciencesEarnings

– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection – – Exercised 40% U.S. Profit-Share option for the HSV helicase primase inhibitor program – – Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 –

Related news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

Stock data

Close
22.50 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States